Gyre Therapeutics (NASDAQ:GYRE) Stock Price Down 4.7% - Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) shares traded down 4.7% on Friday . The stock traded as low as $9.63 and last traded at $9.74. 48,133 shares changed hands during mid-day trading, a decline of 40% from the average session volume of 80,171 shares. The stock had previously closed at $10.22.Get Gyre Therapeutics alerts:Wall Street Analyst Weigh InSeparately, Noble Financial started coverage on shares of Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an "outperform" rating on the stock.View Our Latest Stock Analysis on GYREGyre Therapeutics Stock Down 4.4 %The business's 50 day moving average price is $11.31 and its two-hundred day moving average price is $12.23. Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last issued its quarterly earnings data on Monday, March 17th. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.04 by ($0.03). The business had revenue of $27.87 million during the quarter, compared to the consensus estimate of $23.50 million. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%. Insider Activity at Gyre TherapeuticsIn related news, President Songjiang Ma sold 2,000 shares of the firm's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $12.70, for a total value of $25,400.00. Following the completion of the transaction, the president now owns 2,928,467 shares in the company, valued at $37,191,530.90. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders sold a total of 36,054 shares of company stock worth $411,597 in the last quarter. 19.52% of the stock is owned by insiders. Institutional Inflows and OutflowsLarge investors have recently added to or reduced their stakes in the business. SBI Securities Co. Ltd. bought a new position in Gyre Therapeutics during the 4th quarter worth approximately $1,225,000. FMR LLC bought a new position in Gyre Therapeutics during the 3rd quarter worth approximately $47,000. Charles Schwab Investment Management Inc. raised its holdings in Gyre Therapeutics by 392.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 113,648 shares of the company's stock worth $1,425,000 after purchasing an additional 90,557 shares during the last quarter. State Street Corp raised its holdings in Gyre Therapeutics by 8.8% during the 3rd quarter. State Street Corp now owns 104,490 shares of the company's stock worth $1,310,000 after purchasing an additional 8,412 shares during the last quarter. Finally, Barclays PLC raised its holdings in Gyre Therapeutics by 281.8% during the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after purchasing an additional 6,855 shares during the last quarter. Institutional investors own 23.99% of the company's stock. Gyre Therapeutics Company Profile (Get Free Report)Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.Recommended StoriesFive stocks we like better than Gyre Therapeutics3 Warren Buffett Stocks to Buy NowFedEx Delivers Another Crushing Blow to Its Stock PriceWhat Are Dividend Champions? How to Invest in the ChampionsAnalysts Stay Bullish on Rocket Lab as Signs of a Bottom EmergeUsing the MarketBeat Dividend Yield CalculatorMicron Stock Will Retest All-Time Highs This YearThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Gyre Therapeutics Right Now?Before you consider Gyre Therapeutics, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.While Gyre Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here